{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:45:02Z","timestamp":1785818702116,"version":"3.56.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2336, TP6"],"award-info":[{"award-number":["GRK 2336, TP6"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2336, TP6"],"award-info":[{"award-number":["GRK 2336, TP6"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GB) is the most aggressive type of brain cancer with a devastating prognosis. Myeloid cells, especially monocytes and macrophages, comprise the majority of immune cells within the GB tumour microenvironment, where they contribute to the development of an immunosuppressive milieu hindering potential anti-tumour immune responses. Type I IFNs usually facilitate a pro-inflammatory shift in monocytes and macrophages and allow for anti-tumour functions. Using RNA sequencing, we observed that type I IFN-stimulated genes (ISGs) are globally downregulated in primary human monocytes, but not microglia, co-cultured with GB cells both upon direct cell\u2013cell contact and upon the exchange of soluble factors. Surprisingly, the reduction of type I IFN responses did not result from changes in interferon-\u03b1\/\u03b2-receptor availability and activation. Instead, we identified GM-CSF as a critical, GB cell-derived factor, which decreased ISG expression in monocytes at extremely low concentrations via induction of the TGF-\u03b2 signalling pathway. In line, type I IFN response gene expression and GM-CSF activity in human GB biopsies appeared to be mutually exclusive. Specifically, active GM-CSF signalling appeared to inhibit ISG expression in the same cell as well as in neighbouring monocyte-derived macrophages, which resulted in lower T cell recruitment. In conclusion, our data provide evidence for a so far unknown GM-CSF- and TGF-\u03b2-dependent type I IFN inhibitory mechanism in GB with potential implications for future therapeutic approaches.<\/jats:p>","DOI":"10.1038\/s12276-026-01769-1","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T09:45:08Z","timestamp":1783071908000},"page":"2252-2267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["GM-CSF downregulates type I IFN responses in glioblastoma-associated monocytes"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7992-1448","authenticated-orcid":false,"given":"Sofie P.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-7489","authenticated-orcid":false,"given":"Rebekka","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Weidmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1553-7687","authenticated-orcid":false,"given":"Blerina","family":"Aliraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5188-792X","authenticated-orcid":false,"given":"Megan A.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Sirait-Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-560X","authenticated-orcid":false,"given":"Igor","family":"Ma\u010dinkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Buczynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4893-852X","authenticated-orcid":false,"given":"Irina","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4176-6710","authenticated-orcid":false,"given":"Giulia","family":"Cardamone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2482-5189","authenticated-orcid":false,"given":"Melanie","family":"Flohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7529-1952","authenticated-orcid":false,"given":"Andreas","family":"Weigert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8237-2841","authenticated-orcid":false,"given":"Bernhard","family":"Br\u00fcne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-5259","authenticated-orcid":false,"given":"Tobias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1769_CR1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology 23, 1231\u20131251 (2021).","journal-title":"Neuro-Oncology"},{"key":"1769_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1769_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RGW Verhaak","year":"2010","unstructured":"Verhaak, R. G. W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1015832726054","volume":"58","author":"T Beppu","year":"2002","unstructured":"Beppu, T. et al. Change of oxygen pressure in glioblastoma tissue under various conditions. J. Neurooncol. 58, 47\u201352 (2002).","journal-title":"J. Neurooncol."},{"key":"1769_CR5","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","volume":"31","author":"DF Quail","year":"2017","unstructured":"Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326\u2013341 (2017).","journal-title":"Cancer Cell"},{"key":"1769_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41586-022-01502-8","volume":"606","author":"D Kwon","year":"2022","unstructured":"Kwon, D. Guardians of the brain: how a special immune system protects our grey matter. Nature 606, 22\u201324 (2022).","journal-title":"Nature"},{"key":"1769_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/glia.10147","volume":"40","author":"MB Graeber","year":"2002","unstructured":"Graeber, M. B., Scheithauer, B. W. & Kreutzberg, G. W. Microglia in brain tumors. Glia 40, 252\u2013259 (2002).","journal-title":"Glia"},{"key":"1769_CR8","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","volume":"181","author":"F Klemm","year":"2020","unstructured":"Klemm, F. et al. Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells. Cell 181, 1643\u20131660.e17 (2020).","journal-title":"Cell"},{"key":"1769_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","volume":"24","author":"AR Pombo Antunes","year":"2021","unstructured":"Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595\u2013610 (2021).","journal-title":"Nat. Neurosci."},{"key":"1769_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.it.2024.03.007","volume":"45","author":"S Da Mesquita","year":"2024","unstructured":"Da Mesquita, S. & Rua, R. Brain border-associated macrophages: common denominators in infection, aging, and Alzheimer\u2019s disease? Trends Immunol. 45, 346\u2013357 (2024).","journal-title":"Trends Immunol."},{"key":"1769_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03059-x","volume":"21","author":"R Sun","year":"2024","unstructured":"Sun, R. & Jiang, H. Border-associated macrophages in the central nervous system. J. Neuroinflammation 21, 67 (2024).","journal-title":"J. Neuroinflammation"},{"key":"1769_CR12","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1016\/j.celrep.2016.10.052","volume":"17","author":"RL Bowman","year":"2016","unstructured":"Bowman, R. L. et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep. 17, 2445\u20132459 (2016).","journal-title":"Cell Rep."},{"key":"1769_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002181","volume":"9","author":"EF Simonds","year":"2021","unstructured":"Simonds, E. F. et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J. Immunother. Cancer 9, e002181 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1769_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163446","volume":"133","author":"F Khan","year":"2023","unstructured":"Khan, F. et al. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J. Clin. Invest. 133, e163446 (2023).","journal-title":"J. Clin. Invest."},{"key":"1769_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00920-x","volume":"9","author":"W Zhao","year":"2025","unstructured":"Zhao, W. et al. Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy. NPJ Precis. Oncol. 9, 126 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1769_CR16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264\u20131272 (2013).","journal-title":"Nat. Med."},{"key":"1769_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/carcin\/bgr289","volume":"33","author":"J Zhang","year":"2012","unstructured":"Zhang, J. et al. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2\/CCR2\/interleukin-6 axis. Carcinogenesis 33, 312\u2013319 (2012).","journal-title":"Carcinogenesis"},{"key":"1769_CR18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4049\/jimmunol.1103248","volume":"189","author":"X Ye","year":"2012","unstructured":"Ye, X. et al. Tumor-associated microglia\/macrophages enhance the invasion of glioma stem-like cells via TGF-\u03b21 signaling pathway. J. Immunol. 189, 444\u2013453 (2012).","journal-title":"J. Immunol."},{"key":"1769_CR19","doi-asserted-by":"crossref","unstructured":"Markovic, D. S. et al. Gliomas induce and exploit microglial MT1-MMP expression for tumor expansion. Proc. Natl. Acad. Sci. 106, 12530\u201312535 (2009).","DOI":"10.1073\/pnas.0804273106"},{"key":"1769_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1547466","volume":"16","author":"SP Meyer","year":"2025","unstructured":"Meyer, S. P., Bauer, R., Br\u00fcne, B. & Schmid, T. The role of type I interferon signaling in myeloid anti-tumor immunity. Front. Immunol. 16, 1547466 (2025).","journal-title":"Front. Immunol."},{"key":"1769_CR21","first-page":"258","volume":"147","author":"A Isaacs","year":"1957","unstructured":"Isaacs, A. & Lindenmann, J. Virus interference. I. The interferon. Proc. R. Soc. B Biol. Sci. 147, 258\u2013267 (1957).","journal-title":"Proc. R. Soc. B Biol. Sci."},{"key":"1769_CR22","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1016\/j.cell.2025.06.044","volume":"188","author":"D Boehmer","year":"2025","unstructured":"Boehmer, D. & Zanoni, I. Interferons in health and disease. Cell 188, 4480\u20134504 (2025).","journal-title":"Cell"},{"key":"1769_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias, L. C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5, 375\u2013386 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"1769_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","volume":"6","author":"JW Schoggins","year":"2019","unstructured":"Schoggins, J. W. Interferon-stimulated genes: what do they all do? Annu. Rev. Virol. 6, 567\u2013584 (2019).","journal-title":"Annu. Rev. Virol."},{"key":"1769_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"1769_CR26","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"1769_CR27","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s13365-016-0499-3","volume":"23","author":"Y Garcia-Mesa","year":"2017","unstructured":"Garcia-Mesa, Y. et al. Immortalization of primary microglia: a new platform to study HIV regulation in the central nervous system. J. Neurovirol. 23, 47\u201366 (2017).","journal-title":"J. Neurovirol."},{"key":"1769_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13708","volume":"32","author":"P Zeiner","year":"2025","unstructured":"Zeiner, P. et al. Glioma\u2011associated microglia and macrophages as a potential target for mTOR inhibition in glioblastoma. Mol. Med. Rep. 32, 1\u201313 (2025).","journal-title":"Mol. Med. Rep."},{"key":"1769_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1769_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1158\/1541-7786.MCR-16-0313","volume":"15","author":"M Foroutan","year":"2017","unstructured":"Foroutan, M., Cursons, J., Hediyeh-Zadeh, S., Thompson, E. W. & Davis, M. J. A transcriptional program for detecting TGF\u03b2-induced EMT in cancer. Mol. Cancer Res. 15, 619\u2013631 (2017).","journal-title":"Mol. Cancer Res."},{"key":"1769_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1769_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1203929","volume":"14","author":"J Lim","year":"2023","unstructured":"Lim, J. et al. Harnessing type I interferon-mediated immunity to target malignant brain tumors. Front. Immunol. 14, 1203929 (2023).","journal-title":"Front. Immunol."},{"key":"1769_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/jir.2011.0020","volume":"32","author":"UC M\u00fcller-Quernheim","year":"2012","unstructured":"M\u00fcller-Quernheim, U. C., Potthast, L., M\u00fcller-Quernheim, J. & Zissel, G. Tumor-cell co-culture induced alternative activation of macrophages is modulated by interferons in vitro. J. Interferon Cytokine Res. 32, 169\u2013177 (2012).","journal-title":"J. Interferon Cytokine Res."},{"key":"1769_CR34","doi-asserted-by":"crossref","unstructured":"Karimova, A. F. et al. In vitro functional assays to assess the reciprocal interplay between tumor cells and macrophages. FASEB J. 38, e23730 (2024).","DOI":"10.1096\/fj.202400240R"},{"key":"1769_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116644","volume":"10","author":"F Szulzewsky","year":"2015","unstructured":"Szulzewsky, F. et al. Glioma-associated microglia\/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS ONE 10, e0116644 (2015).","journal-title":"PLoS ONE"},{"key":"1769_CR36","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849.e21 (2019).","journal-title":"Cell"},{"key":"1769_CR37","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41591-024-03215-z","volume":"30","author":"J Klughammer","year":"2024","unstructured":"Klughammer, J. et al. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat. Med. 30, 3236\u20133249 (2024).","journal-title":"Nat. Med."},{"key":"1769_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.585616","volume":"11","author":"T Daubon","year":"2020","unstructured":"Daubon, T., Hemadou, A., Romero Garmendia, I. & Saleh, M. Glioblastoma immune landscape and the potential of new immunotherapies. Front. Immunol. 11, 585616 (2020).","journal-title":"Front. Immunol."},{"key":"1769_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111769","volume":"41","author":"D Kwart","year":"2022","unstructured":"Kwart, D. et al. Cancer cell-derived type I interferons instruct tumor monocyte polarization. Cell Rep. 41, 111769 (2022).","journal-title":"Cell Rep."},{"key":"1769_CR40","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/neuonc\/nop023","volume":"12","author":"JC Rodrigues","year":"2010","unstructured":"Rodrigues, J. C. et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro-Oncology 12, 351\u2013365 (2010).","journal-title":"Neuro-Oncology"},{"key":"1769_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.dci.2003.09.010","volume":"28","author":"D Barreda","year":"2004","unstructured":"Barreda, D. Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. 28, 509\u2013554 (2004).","journal-title":"Dev. Comp. Immunol."},{"key":"1769_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58131-2","volume":"10","author":"N Lotfi","year":"2020","unstructured":"Lotfi, N., Zhang, G.-X., Esmaeil, N. & Rostami, A. Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes. Sci. Rep. 10, 1567 (2020).","journal-title":"Sci. Rep."},{"key":"1769_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jlb.48.1.43","volume":"48","author":"LA Falk","year":"1990","unstructured":"Falk, L. A. & Vogel, S. N. Differential production of IFN-\u03b1\/\u03b2 by CSF-1- and GM-CSF-derived macrophages. J. Leukoc. Biol. 48, 43\u201349 (1990).","journal-title":"J. Leukoc. Biol."},{"key":"1769_CR44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1189\/jlb.1108702","volume":"86","author":"AJ Fleetwood","year":"2009","unstructured":"Fleetwood, A. J., Dinh, H., Cook, A. D., Hertzog, P. J. & Hamilton, J. A. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on Type I interferon signaling. J. Leukoc. Biol. 86, 411\u2013421 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"1769_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02674","volume":"10","author":"SA Read","year":"2019","unstructured":"Read, S. A. et al. Macrophage coordination of the interferon lambda immune response. Front. Immunol. 10, 2674 (2019).","journal-title":"Front. Immunol."},{"key":"1769_CR46","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1089\/jir.2006.0170","volume":"27","author":"S Kasper","year":"2007","unstructured":"Kasper, S. et al. Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation. J. Interferon Cytokine Res. 27, 947\u2013960 (2007).","journal-title":"J. Interferon Cytokine Res."},{"key":"1769_CR47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","volume":"134","author":"J Massagu\u00e9","year":"2008","unstructured":"Massagu\u00e9, J. TGF\u03b2 in cancer. Cell 134, 215\u2013230 (2008).","journal-title":"Cell"},{"key":"1769_CR48","doi-asserted-by":"publisher","first-page":"52294","DOI":"10.18632\/oncotarget.10561","volume":"7","author":"F Zhang","year":"2016","unstructured":"Zhang, F. et al. TGF-\u03b2 induces M2-like macrophage polarization via SNAIL-mediated suppression of a pro-inflammatory phenotype. Oncotarget 7, 52294\u201352306 (2016).","journal-title":"Oncotarget"},{"key":"1769_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng, Z. et al. TGF-\u03b2 signaling in health, disease and therapeutics. Signal Transduct. Target. Ther. 9, 61 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1769_CR50","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.4049\/jimmunol.1701325","volume":"200","author":"JR Grunwell","year":"2018","unstructured":"Grunwell, J. R. et al. TGF-\u03b21 suppresses the type I IFN response and induces mitochondrial dysfunction in alveolar macrophages. J. Immunol. 200, 2115\u20132128 (2018).","journal-title":"J. Immunol."},{"key":"1769_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11998-w","volume":"10","author":"MV Guerin","year":"2019","unstructured":"Guerin, M. V. et al. TGF\u03b2 blocks IFN\u03b1\/\u03b2 release and tumor rejection in spontaneous mammary tumors. Nat. Commun. 10, 4131 (2019).","journal-title":"Nat. Commun."},{"key":"1769_CR52","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/s41593-019-0532-y","volume":"22","author":"R Sankowski","year":"2019","unstructured":"Sankowski, R. et al. Mapping microglia states in the human brain through the integration of high-dimensional techniques. Nat. Neurosci. 22, 2098\u20132110 (2019).","journal-title":"Nat. Neurosci."},{"key":"1769_CR53","doi-asserted-by":"publisher","first-page":"e242","DOI":"10.1038\/emm.2016.64","volume":"48","author":"I-S Hong","year":"2016","unstructured":"Hong, I.-S. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp. Mol. Med. 48, e242\u2013e242 (2016).","journal-title":"Exp. Mol. Med."},{"key":"1769_CR54","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/bloodadvances.2017006858","volume":"1","author":"E Ribechini","year":"2017","unstructured":"Ribechini, E. et al. Novel GM-CSF signals via IFN-\u03b3R\/IRF-1 and AKT\/mTOR license monocytes for suppressor function. Blood Adv. 1, 947\u2013960 (2017).","journal-title":"Blood Adv."},{"key":"1769_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901277","volume":"13","author":"A Kumar","year":"2022","unstructured":"Kumar, A., Taghi Khani, A., Sanchez Ortiz, A. & Swaminathan, S. GM-CSF: a double-edged sword in cancer immunotherapy. Front. Immunol. 13, 901277 (2022).","journal-title":"Front. Immunol."},{"key":"1769_CR56","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","volume":"13","author":"SH Wrzesinski","year":"2007","unstructured":"Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-\u03b2 and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262\u20135270 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1769_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jneuroim.2010.04.003","volume":"225","author":"T Avril","year":"2010","unstructured":"Avril, T. et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions. J. Neuroimmunol. 225, 22\u201333 (2010).","journal-title":"J. Neuroimmunol."},{"key":"1769_CR58","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003519","volume":"10","author":"P Hamon","year":"2022","unstructured":"Hamon, P. et al. TGF\u03b2 receptor inhibition unleashes interferon-\u03b2 production by tumor-associated macrophages and enhances radiotherapy efficacy. J. Immunother. Cancer 10, e003519 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1769_CR59","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ccell.2023.04.018","volume":"41","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer Cell 41, 1073\u20131090.e12 (2023).","journal-title":"Cancer Cell"},{"key":"1769_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113560","volume":"42","author":"S Miyauchi","year":"2023","unstructured":"Miyauchi, S., Arimoto, K., Liu, M., Zhang, Y. & Zhang, D.-E. Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18. Cell Rep. 42, 113560 (2023).","journal-title":"Cell Rep."},{"key":"1769_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1121864","volume":"14","author":"R Bauer","year":"2023","unstructured":"Bauer, R. et al. Hypoxia-altered cholesterol homeostasis enhances the expression of interferon-stimulated genes upon SARS-CoV-2 infections in monocytes. Front. Immunol. 14, 1121864 (2023).","journal-title":"Front. Immunol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01769-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01769-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01769-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:09:10Z","timestamp":1785816550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01769-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01769-1","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}